Shaanxi Meibang Pharmaceutical (SH:605033) Zheng Quan Zhi Xing·2025-07-08 16:19Core Viewpoint - The announcement details the progress of share reduction by major shareholders of Shaanxi Meibang Pharmaceutical Group Co., Ltd., indicating a decrease in their holdings and the implications of this reduction on the company's equity structure [1][2]. Shareholder Holding Situation - Meiping Consulting holds 3,510,000 shares, accounting for 2.60% of the total share capital, while Meifu Consulting holds 4,890,000 shares, representing 3.62% of the total share capital. Both holdings originated from shares acquired before the company's initial public offering (IPO) [1][2]. Reduction Plan Progress - Meiping Consulting plans to reduce its holdings by up to 1,248,821 shares (0.92% of total share capital), with a breakdown of 416,274 shares through centralized bidding and 832,547 shares via block trading. Meifu Consulting intends to reduce its holdings by up to 1,739,811 shares (1.29%), with 579,937 shares through centralized bidding and 1,159,874 shares via block trading [1][2]. - As of the announcement date, Meiping Consulting has reduced its holdings by 291,300 shares (0.22%), decreasing its ownership from 2.60% to 2.38%. Meifu Consulting has reduced its holdings by 405,900 shares (0.30%), lowering its ownership from 3.62% to 3.32%. The combined ownership of Meiping Consulting, Meifu Consulting, and their concerted parties has decreased from 69.09% to 68.57% [1][3]. Compliance with Regulations - The reduction in shareholding has triggered a change in equity structure that meets the regulatory requirements outlined in the "Management Measures for the Acquisition of Listed Companies" [1][3].